CordenPharma announces an expansion of manufacturing capabilities due to the recent acquisition by International Chemical Investors Group (ICIG) of Farchemia from the Tessenderlo Group, completed on December 5th, 2012.
Farchemia, located in Bergamo, Italy, brings to CordenPharma expanded capabilities in developing and manufacturing advanced intermediates and APIs for the pharmaceutical industry in all major markets. Farchemia’s portfolio is comprised of cGMP custom synthesis from lab to multi-tonne scale, multi-step API process development, contract manufacturing, and full suite of proprietary generic APIs. Farchemia employs approximately 150 people and generates nearly 50 Million Euro in annual sales.
“Farchemia is an excellent fit to complement and expand the CordenPharma portfolio with a legacy of experience in manufacturing small molecule APIs for both proprietary and custom products. We look forward to integrating it into the CordenPharma network of expertise”, says Wolfgang Niedermaier, President of CordenPharma.